InventageLab Collaborates with Yuhan Corporation to Develop Long-Acting GLP-1 Injectable Agent

Invention Lab has partnered with Yuhan Corporation to develop a long-acting injectable formulation containing glucagon-like peptide (GLP)-1, which has recently gained attention as a treatment for diabetes and obesity.

Kim Joo-hee, CEO of Inventage Lab, and Kim Yeol-hong, President of Yuhan Corporation, are posing for a commemorative photo at the signing ceremony for the joint development contract of a long-acting injectable drug for diabetes and obesity.
[Photo by Inventage Lab]

Under this agreement, Invention Lab will be responsible for formulation optimization, preclinical trials, and initial product manufacturing. Yuhan Corporation will handle the costs of Phase 1 clinical trials, as well as late-stage development including Phase 3 clinical trials for regulatory approval, product registration, and commercialization.

Invention Lab is currently conducting preclinical trials for ‘IVL3021,’ a long-acting injectable obesity treatment based on semaglutide, a GLP-1 compound with a one-month dosing cycle. Semaglutide is the main ingredient in Novo Nordisk’s obesity treatment ‘Wegovy,’ which has demonstrated a 14.9% weight loss effect over one year along with efficacy in cardiovascular disease.

Jo Wook-je, CEO of Yuhan Corporation, stated, “The GLP-1 long-acting injectable developed with Invention Lab’s differentiated technology is a product line that meets the diverse needs and demands of patients in the rapidly growing obesity treatment market. It is expected to provide effective treatment and improve the quality of life for patients with obesity and diabetes.”

Kim Joo-hee, CEO of Invention Lab, said, “Through the strategic partnership with Yuhan Corporation, we expect to offer a new option in the obesity and diabetes treatment market, where continuous medication is required, by providing a long-acting injectable. We will work as one team with Yuhan Corporation to maximize the value of the drug and succeed in global commercialization, striving to make this project known as the second ‘Reclaza.’”